Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
11 hedge funds and large institutions have $5.93M invested in Landos Biopharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
38% more funds holding
Funds holding: 8 → 11 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
5% less capital invested
Capital invested by funds: $6.27M → $5.93M (-$340K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$57.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$49.2K |
| 3 |
Renaissance Technologies
New York
|
+$40.1K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $5.77M | – | – | – |
|
|
2
Macquarie Group
Sydney, NSW 2000,
Australia
| $57K | +$57.5K | +14,718 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $48.8K | +$49.2K | +12,604 | New |
|
|
4
Renaissance Technologies
New York
| $40K | +$40.1K | +10,260 | New |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | +$2.33K | +597 | +98% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4.58K | -$1.41K | -362 | -23% |
|
7
JP Morgan Chase
New York
| $228 | – | – | – |
|
8
BlackRock
New York
| $163 | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $144 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $35 | – | – | – |
|
LABP Hedge Fund Activity: Q3 2023 in Review
11 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q3 2023, worth a combined $5.93M — down 5.4% from $6.27M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LABP positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Macquarie Group, opening a new position worth an estimated $57.5K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.41K.
- 11 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q3 2023, up from 8 in Q2 2023.
- Funds reported $5.93M of Landos Biopharma, Inc. Common Stock stock for Q3 2023, down 5.4% quarter-over-quarter.
- 3 funds opened new Landos Biopharma, Inc. Common Stock positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q3 2023 was Macquarie Group, an estimated $57.5K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q3 2023 was Tower Research Capital (TRC), an estimated $1.41K sold.
Based on aggregated 13F filings for Q3 2023.